Publications by authors named "Y Tsuchiya-Kawano"
Background: The efficacy and safety of sotorasib plus platinum-doublet chemotherapy in KRAS G12C-mutated non-squamous non-small cell lung cancer (non-Sq NSCLC) were previously reported with limited follow-up period.
Method: SCARLET was a single-arm phase II study of chemotherapy-naïve patients with KRAS G12C-mutated non-Sq NSCLC. Participants received sotorasib 960 mg daily plus four cycles of carboplatin (area under the curve, 5)/pemetrexed 500 mg/m, followed by sotorasib/pemetrexed until disease progression.
Article Synopsis
- Immune checkpoint inhibitors combined with chemotherapy (ICI-chemo) are a standard treatment for non-small cell lung cancer (NSCLC), but the effectiveness compared to ipilimumab and nivolumab (I-N) for patients with a PD-L1 tumor proportion score (TPS) of 1-49% was not previously assessed.
- A study involving 401 NSCLC patients analyzed treatment outcomes, finding that median overall survival (OS) was similar between the ICI-chemo group (21.0 months) and the I-N group (20.0 months), with no significant survival differences after matching for confounders.
- However, in patients with a TPS of 25-49%, the ICI-chemo group showed a
Article Synopsis
- The study investigates the impact of dual immunotherapy (nivolumab and ipilimumab) along with platinum-based chemotherapy on patients with untreated brain metastases from non-small cell lung cancer (NSCLC).
- In total, 30 patients were enrolled, and the results showed a 50% intracranial response rate with a 20% rate of complete response, indicating effectiveness in targeting brain lesions.
- The findings suggest that this treatment combination has promising potential for managing NSCLC patients with brain metastases, achieving a median intracranial progression-free survival of 8.1 months.
Background: Concurrent chemoradiotherapy is the standard therapy for locally advanced non-small cell lung cancer (NSCLC). However, there is little evidence supporting its use in older adults. Low-dose daily carboplatin combined with thoracic radiotherapy is considered a standard regimen for this population.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on predicting the prognosis of stage IV lung cancer patients using machine learning algorithms that can be generalized across multiple institutions.
- It involved a large cohort of over 6,700 patients and assessed the algorithms' performance based on survival predictions over various time frames.
- The results indicate a high accuracy of the algorithms, with areas under the curve ranging from 0.83 to 0.90 for different survival days, demonstrating potential for broader clinical application.